Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felzartamab in Adults With IgA Nephropathy (PREVAIL)
NCT06935357Phase 3Recruiting
- Sponsor
- Biogen
- Start
- May 2025
- Primary completion
- May 2027
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of felzartamab in immunoglobulin A nephropathy (IgAN) (4 cohorts), sponsored by Biogen. Primary endpoint: Urine Protein: Creatinine Ratio at 36 weeks. Started May 2025; status: recruiting.
02
Drugs
felzartamab
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06935357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06935357.